adlitterio66339

About adlitterio66339

This author has not yet filled in any details.
So far adlitterio66339 has created 792 blog entries.

19 06, 2025

Marianna Peroni et al., BRAF fusion as resistance mechanism to osimertinib in EGFR-mutated NSCLC: a case report and review of literature

adlitterio663392025-06-19T16:29:03+02:00

18 06, 2025

Alessandro Vanoli et al., HER2, HER3 and mismatch repair protein expression in stage IV small bowel adenocarcinoma: results from a multicenter series.

adlitterio663392025-06-18T16:25:33+02:00

28 05, 2025

Lorenzo Scappaticcio et al., Patient-specific factors, patient preference, and nodule size as implications in the initial surgery of high risk indeterminate thyroid nodules.

adlitterio663392025-05-28T16:23:48+02:00

28 05, 2025

Maria Antonietta Castaldi et al., BRAF V600E mutation associated with papillary high-grade serous ovarian cystadenocarcinoma in a 22q11.2DS patient

adlitterio663392025-05-28T16:22:02+02:00

22 05, 2025

Diatech Pharmacogenetics will join the European Society of Human Genetics Congress 2025
Diatech Pharmacogenetics will join the European Society of Human Genetics Congress 2025

Nachrichten, Veranstaltungen

Diatech Pharmacogenetics will join the European Society of Human Genetics Congress 2025

adlitterio663392025-05-22T12:12:47+02:00

20 05, 2025

Mariavittoria Vescovo et al., Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications

adlitterio663392025-05-20T16:17:56+02:00

20 05, 2025

UGT1A1 & DPYD: Safer chemotherapy starts with genotyping

adlitterio663392025-06-23T16:27:31+02:00

13 05, 2025

Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare

adlitterio663392025-05-13T10:28:55+02:00

8 05, 2025

Advancing Precision Medicine: Preventing ADRs with Pharmacogenomic Panel Testing
Advancing Precision Medicine: Preventing ADRs with Pharmacogenomic Panel Testing

Nachrichten

Advancing Precision Medicine: Preventing ADRs with Pharmacogenomic Panel Testing

adlitterio663392025-05-08T09:27:20+02:00

7 05, 2025

Laura Antolino et al., TP53 Arg72Pro Polymorphism and Pancreatic Cancer Susceptibility: Assessing rs1042522 as a Risk Factor for Pancreatic Cancer

adlitterio663392025-05-07T16:16:46+02:00

Vorheriges 123 Nächstes